Xencor (XNCR)
Licenses Fc-engineered antibody technology to partners while advancing a wholly-owned bispecific pipeline.
$25.08
vs last close+0.05 (+0.21%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 43 days
EPS estimate
−$0.35
Revenue estimate
$59.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.62−$0.66−$0.41−$0.08−$0.09−$1.71−$0.29Pending
Estimate−$0.81−$0.63−$0.78−$0.72−$0.64−$0.65−$0.80−$0.35
Surprise+23.5%−4.8%+47.4%+88.9%+85.9%−163.1%+63.8%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$70.0M$32.7M$43.6M$21.0M$28.2M$4.5M$51.2MPending
Estimate$16.9M$22.5M$24.4M$30.0M$30.0M$27.9M$18.9M$59.1M
Surprise+313.3%+45.5%+78.9%−29.9%−5.8%−83.8%+171.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.80 | — | — |
| Sep 2028 | −$0.81 | — | — |
| Jun 2028 | −$0.81 | — | — |
| Mar 2028 | −$0.86 | — | — |
| Dec 2027 | −$0.97 | — | — |
| Sep 2027 | −$0.87 | — | — |
| Jun 2027 | −$0.94 | — | — |
| Mar 2027 | −$0.94 | — | — |
| Dec 2026 | −$0.77 | — | — |
| Nov 2026 | −$0.35 | — | — |
| Aug 2026 | −$0.80 | −$0.29 | +63.8% |
| May 2026 | −$0.65 | −$1.71 | −163.1% |
| Feb 2026 | −$0.64 | −$0.09 | +85.9% |
| Nov 2025 | −$0.72 | −$0.08 | +88.9% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.80 | — | — | $15.5M | — | — | — |
| Sep 2028 | −$0.81 | — | — | $15.5M | — | — | — |
| Jun 2028 | −$0.81 | — | — | $15.5M | — | — | — |
| Mar 2028 | −$0.86 | — | — | $15.5M | — | — | — |
| Dec 2027 | −$0.97 | — | — | $16.5M | — | — | — |
| Sep 2027 | −$0.87 | — | — | $30.5M | — | — | — |
| Jun 2027 | −$0.94 | — | — | $15.8M | — | — | — |
| Mar 2027 | −$0.94 | — | — | $14.9M | — | — | — |
| Dec 2026 | −$0.77 | — | — | $28.4M | — | — | — |
| Nov 4, 2026 | −$0.35 | — | — | $59.1M | — | — | — |
| Aug 5, 2026 | −$0.80 | −$0.29 | +63.8% | $18.9M | $51.2M | +171.2% | +0.8% |
| May 6, 2026 | −$0.65 | −$1.71 | −163.1% | $27.9M | $4.5M | −83.8% | +1.3% |
| Feb 25, 2026 | −$0.64 | −$0.09 | +85.9% | $30.0M | $28.2M | −5.8% | +1.4% |
| Nov 5, 2025 | −$0.72 | −$0.08 | +88.9% | $30.0M | $21.0M | −29.9% | +4.9% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 23, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 24, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 25, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 7, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 28, 2017 | |||||||
| Nov 2, 2016 | |||||||
| Aug 2, 2016 | |||||||
| May 2, 2016 | |||||||
| Mar 7, 2016 | |||||||
| Nov 3, 2015 | |||||||
| Aug 4, 2015 |